About ImYoo

The startup has developed a biodiscovery platform that utilizes single-cell multi-omic analysis on small blood volumes self-collected at home. This technology enables users to generate high-fidelity longitudinal data to identify critical biomarkers during significant health events, such as autoimmune flares and adverse therapeutic side effects.

```xml <problem> Current methods for collecting patient data are often limited to clinical settings, resulting in infrequent and potentially biased snapshots of an individual's health. This lack of continuous, real-world data hinders the ability to understand the dynamic nature of diseases and develop more precise and targeted treatments. </problem> <solution> ImYoo is developing a patient-enabled biodiscovery platform that facilitates longitudinal collection and analysis of patient data. The platform allows individuals to self-collect small blood samples at home using easy-to-use kits, enabling frequent and convenient repeat sampling. These samples are then processed using single-cell RNA sequencing to generate high-resolution immune profiles. ImYoo leverages machine learning models trained on a database of immune profiles to analyze the complex single-cell RNA sequencing data. This approach aims to capture relevant health events as they happen, understand the complexities of diseases, and ultimately enable precision diagnostics and therapies. </solution> <features> - At-home blood self-collection kits for convenient and painless sample acquisition - Single-cell RNA sequencing to generate high-resolution immune profiles - Longitudinal data collection to capture changes in an individual's biology over time - Machine learning models for analyzing complex single-cell RNA sequencing data - Capability to identify critical biomarkers during key disease events, such as autoimmune flares - Personalized reports on RNA and cell numbers compared to others in the database (opt-in) - End-to-end workflow from sample collection to data analysis </features> <target_audience> ImYoo serves both patients interested in participating in research and researchers seeking access to unique patient data for biomarker discovery, individual baselining, and patient stratification. </target_audience> <revenue_model> ImYoo generates revenue by offering researchers access to its database of single-cell transcriptomics data and by providing services to design and execute bespoke studies leveraging its network of patient scientists and analytical capabilities. Participants in IBD/RA studies receive compensation in the form of gift cards ($125 for 3 samples, $250 for 6 samples). </revenue_model> ```

What does ImYoo do?

Where is ImYoo located?

ImYoo is based in San Francisco, United States.

When was ImYoo founded?

ImYoo was founded in 2021.

How much funding has ImYoo raised?

ImYoo has raised 2110000.

Location

San Francisco, United States

Founded

2021

Funding

2110000

Employees

6 employees

Major Investors

Illumina Accelerator

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

ImYoo

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

imyoo.health 500+

Crunchbase

Founded 2021 – San Francisco, United States

Funding

Estimated Funding

$2M+

Major Investors

Illumina Accelerator

Team (5+)

No team information available.

Company Description

Problem

Current methods for collecting patient data are often limited to clinical settings, resulting in infrequent and potentially biased snapshots of an individual's health. This lack of continuous, real-world data hinders the ability to understand the dynamic nature of diseases and develop more precise and targeted treatments.

Solution

ImYoo is developing a patient-enabled biodiscovery platform that facilitates longitudinal collection and analysis of patient data. The platform allows individuals to self-collect small blood samples at home using easy-to-use kits, enabling frequent and convenient repeat sampling. These samples are then processed using single-cell RNA sequencing to generate high-resolution immune profiles. ImYoo leverages machine learning models trained on a database of immune profiles to analyze the complex single-cell RNA sequencing data. This approach aims to capture relevant health events as they happen, understand the complexities of diseases, and ultimately enable precision diagnostics and therapies.

Features

At-home blood self-collection kits for convenient and painless sample acquisition

Single-cell RNA sequencing to generate high-resolution immune profiles

Longitudinal data collection to capture changes in an individual's biology over time

Machine learning models for analyzing complex single-cell RNA sequencing data

Capability to identify critical biomarkers during key disease events, such as autoimmune flares

Personalized reports on RNA and cell numbers compared to others in the database (opt-in)

End-to-end workflow from sample collection to data analysis

Target Audience

ImYoo serves both patients interested in participating in research and researchers seeking access to unique patient data for biomarker discovery, individual baselining, and patient stratification.

Revenue Model

ImYoo generates revenue by offering researchers access to its database of single-cell transcriptomics data and by providing services to design and execute bespoke studies leveraging its network of patient scientists and analytical capabilities. Participants in IBD/RA studies receive compensation in the form of gift cards ($125 for 3 samples, $250 for 6 samples).